Liu Zhibo, Pourghiasian Maral, Bénard François, Pan Jinhe, Lin Kuo-Shyan, Perrin David M
Chemistry Department, University of British Columbia, Vancouver, British Columbia, Canada; and.
BC Cancer Agency Research Centre, Vancouver, British Columbia, Canada.
J Nucl Med. 2014 Sep;55(9):1499-505. doi: 10.2967/jnumed.114.137836. Epub 2014 Jun 26.
Recent studies have highlighted the high sensitivity of PET imaging with (68)Ga-labeled octreotide derivatives for the detection and staging of neuroendocrine tumors. A somatostatin receptor ligand that is easily radiolabeled with (18)F-fluoride could improve the availability of PET imaging of neuroendocrine tumors. We report an alkyltrifluoroborate-octreotate conjugate that is radiolabeled in a 1-step (18)F exchange reaction in high yield and with high specific activity.
We conjugated a new alkyltrifluoroborate to octreotate to obtain AMBF3-TATE, which was stored in 50-nmol aliquots for radiolabeling. (18)F labeling was performed by (18)F-(19)F isotope exchange with (18)F-fluoride, and the tracer was purified by C18 cartridge separation. The radiochemical yield was 20%-25%. PET imaging and biodistribution were performed on mice bearing AR42J tumor xenografts.
AMBF3-TATE bound the somatostatin receptor subtype 2 with high affinity (inhibition constant, 0.13 ± 0.03 nM). Starting with 29.6-37 GBq (0.8-1 Ci) of (18)F-fluoride, more than 7.4 GBq (>200 mCi) of (18)F-AMBF3-TATE were obtained in 25 min (n = 5) with greater than 99% radiochemical purity at high specific activity (>111 GBq [3 Ci]/μmol). (18)F-AMBF3-TATE was stable in plasma. PET imaging and biodistribution showed rapid renal excretion with low liver activity. High tumor uptake (10.11% ± 1.67% injected dose/g, n = 5) was detected at 60 min after injection. Bone uptake was negligible. Tumor-to-liver, tumor-to-blood, tumor-to-muscle, and tumor-to-bone ratios (at 60 min) were 26.2 ± 0.8, 25.1 ± 1.0, 89.0 ± 3.1, and 21.3 ± 3.6, respectively.
(18)F-AMBF3-TATE was radiolabeled in high yield and at high specific activity, did not require high-performance liquid chromatography purification, exhibited unexpectedly high binding affinity to somatostatin receptor subtype 2, and showed excellent pharmacokinetic properties in vivo, with high tumor uptake and high contrast ratios.
近期研究强调了使用(68)Ga标记的奥曲肽衍生物进行PET成像对神经内分泌肿瘤检测和分期具有高敏感性。一种易于用(18)F-氟化物进行放射性标记的生长抑素受体配体可提高神经内分泌肿瘤PET成像的可用性。我们报告了一种烷基三氟硼酸盐-奥曲肽共轭物,其在一步(18)F交换反应中以高产率和高比活进行放射性标记。
我们将一种新的烷基三氟硼酸盐与奥曲肽共轭以获得AMBF3-TATE,将其以50 nmol的分装量储存用于放射性标记。通过与(18)F-氟化物进行(18)F-(19)F同位素交换进行(18)F标记,并通过C18柱分离纯化示踪剂。放射化学产率为20%-25%。对携带AR42J肿瘤异种移植物的小鼠进行PET成像和生物分布研究。
AMBF3-TATE以高亲和力结合生长抑素受体2亚型(抑制常数,0.13±0.03 nM)。从29.6-37 GBq(0.8-1 Ci)的(18)F-氟化物开始,在25分钟内获得了超过7.4 GBq(>200 mCi)的(18)F-AMBF3-TATE(n = 5),在高比活(>111 GBq [3 Ci]/μmol)下放射化学纯度大于99%。(18)F-AMBF3-TATE在血浆中稳定。PET成像和生物分布显示肾脏快速排泄且肝脏活性低。注射后60分钟检测到高肿瘤摄取(10.11%±1.67%注射剂量/克,n = 5)。骨摄取可忽略不计。肿瘤与肝脏、肿瘤与血液、肿瘤与肌肉以及肿瘤与骨的比值(60分钟时)分别为26.2±0.8、25.1±1.0、89.0±3.1和21.3±3.6。
(18)F-AMBF3-TATE以高产率和高比活进行放射性标记,无需高效液相色谱纯化,对生长抑素受体2亚型表现出出乎意料的高结合亲和力,并且在体内显示出优异的药代动力学特性,具有高肿瘤摄取和高对比度。